Mark R. Davis

10.8k total citations · 2 hit papers
119 papers, 4.8k citations indexed

About

Mark R. Davis is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, Mark R. Davis has authored 119 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Molecular Biology, 38 papers in Cardiology and Cardiovascular Medicine and 30 papers in Genetics. Recurrent topics in Mark R. Davis's work include Muscle Physiology and Disorders (29 papers), Cardiomyopathy and Myosin Studies (27 papers) and Neurogenetic and Muscular Disorders Research (23 papers). Mark R. Davis is often cited by papers focused on Muscle Physiology and Disorders (29 papers), Cardiomyopathy and Myosin Studies (27 papers) and Neurogenetic and Muscular Disorders Research (23 papers). Mark R. Davis collaborates with scholars based in Australia, United States and United Kingdom. Mark R. Davis's co-authors include Bryan Williams, Morris J. Brown, Simon Thom, Nigel G. Laing, N. Poulter, P S Sever, Jane Potter, GT McInnes, Gordon T. McInnes and Neil R Poulter and has published in prestigious journals such as The Lancet, Brain and Neurology.

In The Last Decade

Mark R. Davis

115 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV

2004 872 citations Mark R. Davis et al. profile →
British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

2004 591 citations Mark R. Davis et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark R. Davis Australia	32	2.1k	1.8k	663	504	454	119	4.8k
Mansoureh Eghbali United States	39	1.6k 0.8×	1.9k 1.1×	581 0.9×	639 1.3×	74 0.2×	114	5.0k
Pierre Meneton France	38	1.3k 0.6×	2.8k 1.6×	235 0.4×	157 0.3×	478 1.1×	92	5.4k
Thomas Hampton United States	30	746 0.4×	1.2k 0.7×	248 0.4×	500 1.0×	186 0.4×	88	3.5k
Ian N.M. Day United Kingdom	44	659 0.3×	2.9k 1.7×	2.4k 3.6×	433 0.9×	162 0.4×	162	7.5k
Vicky A. Cameron New Zealand	35	1.4k 0.7×	1.2k 0.7×	254 0.4×	259 0.5×	46 0.1×	124	3.8k
Alan B. Weder United States	34	1.6k 0.8×	1.0k 0.6×	1.1k 1.7×	333 0.7×	42 0.1×	94	4.7k
Masahiko Yamamoto Japan	42	462 0.2×	2.3k 1.3×	369 0.6×	1.5k 3.0×	700 1.5×	200	6.2k
Carlos J. Pirola Argentina	52	1.3k 0.6×	2.5k 1.4×	561 0.8×	389 0.8×	151 0.3×	184	9.3k
Sandra J. Hasstedt United States	41	764 0.4×	1.3k 0.7×	1.5k 2.3×	85 0.2×	407 0.9×	120	4.7k
Espen E. Spangenburg United States	41	521 0.2×	2.5k 1.4×	443 0.7×	259 0.5×	202 0.4×	112	4.8k

Countries citing papers authored by Mark R. Davis

Since Specialization

Citations

This map shows the geographic impact of Mark R. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Davis more than expected).

Fields of papers citing papers by Mark R. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Davis. The network helps show where Mark R. Davis may publish in the future.

Co-authorship network of co-authors of Mark R. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Davis. A scholar is included among the top collaborators of Mark R. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Davis. Mark R. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Davis, Mark R., et al.. (2023). Novel SERAC1 Variant Presenting With Adult-Onset Extrapyramidal Dystonia-Parkinsonism Phenotype. Neurology Genetics. 9(2). e200067–e200067. 1 indexed citations

Johnsen, R., Mark R. Davis, U. Moore, et al.. (2022). Identification of a novel heterozygous DYSF variant in a large family with a dominantly‐inherited dysferlinopathy. Neuropathology and Applied Neurobiology. 48(7). e12846–e12846. 8 indexed citations

Servián‐Morilla, Emilia, Eloy Rivas, Fathimath Faiz, et al.. (2022). A KLHL40 3’ UTR splice-altering variant causes milder NEM8, an under-appreciated disease mechanism. Human Molecular Genetics. 32(7). 1127–1136. 7 indexed citations

Malfatti, Edoardo, Sonia Nouioua, Emmanuel Fournier, et al.. (2021). A TOR1AIP1 variant segregating with an early onset limb girdle myasthenia—Support for the role of LAP1 in NMJ function and disease. Neuropathology and Applied Neurobiology. 48(1). e12743–e12743. 6 indexed citations

Beecroft, Sarah J., Phillipa J. Lamont, Samantha Edwards, et al.. (2020). The Impact of Next-Generation Sequencing on the Diagnosis, Treatment, and Prevention of Hereditary Neuromuscular Disorders. Molecular Diagnosis & Therapy. 24(6). 641–652. 7 indexed citations

Akesson, Lauren, Adam Bournazos, Andrew Fennell, et al.. (2020). Rapid exome sequencing and adjunct RNA studies confirm the pathogenicity of a novel homozygous ASNS splicing variant in a critically ill neonate. Human Mutation. 41(11). 1884–1891. 8 indexed citations

Cabrera‐Serrano, Macarena, David Coote, Dimitar N. Azmanov, et al.. (2020). A homozygous UBA5 pathogenic variant causes a fatal congenital neuropathy. Journal of Medical Genetics. 57(12). 835–842. 19 indexed citations

Jones, Hannah, Samantha J. Bryen, Leigh B. Waddell, et al.. (2019). Importance of muscle biopsy to establish pathogenicity of DMD missense and splice variants. Neuromuscular Disorders. 29(12). 913–919. 11 indexed citations

Ong, Royston, Samantha Edwards, Denise Howting, et al.. (2019). Study protocol of a multicentre cohort pilot study implementing an expanded preconception carrier-screening programme in metropolitan and regional Western Australia. BMJ Open. 9(6). e028209–e028209. 5 indexed citations

10.

Coote, David, Mark R. Davis, Macarena Cabrera‐Serrano, et al.. (2018). CUGC for Duchenne muscular dystrophy (DMD). European Journal of Human Genetics. 26(5). 749–757. 2 indexed citations

11.

Baynam, Gareth, Nicholas Pachter, F. Ellis McKenzie, et al.. (2015). AB002. The rare and undiagnosed diseases diagnostic service. Annals of Translational Medicine. 4(2). 3–3.

12.

Baynam, Gareth, Mark R. Davis, Kym Mina, et al.. (2015). A germline MTOR mutation in Aboriginal Australian siblings with intellectual disability, dysmorphism, macrocephaly, and small thoraces. American Journal of Medical Genetics Part A. 167(7). 1659–1667. 31 indexed citations

13.

Nowak, Kristen L., Mark R. Davis, Carina Wallgren‐Pettersson, Phillipa J. Lamont, & Nigel G. Laing. (2015). Clinical utility gene card for: Nemaline myopathy – update 2015. European Journal of Human Genetics. 23(11). 4–5. 10 indexed citations

14.

Clarke, Nigel F., Kimberly Amburgey, James W. Teener, et al.. (2013). A novel mutation expands the genetic and clinical spectrum of MYH7-related myopathies. Neuromuscular Disorders. 23(5). 432–436. 29 indexed citations

15.

Ravenscroft, Gianina, Elizabeth M. Thompson, Emily J. Todd, et al.. (2012). Whole exome sequencing in foetal akinesia expands the genotype–phenotype spectrum of GBE1 glycogen storage disease mutations. Neuromuscular Disorders. 23(2). 165–169. 29 indexed citations

16.

Kankirawatana, Pongkiat, Helen Leonard, Carolyn Ellaway, et al.. (2006). Early progressive encephalopathy in boys and MECP2 mutations. Neurology. 67(1). 164–166. 71 indexed citations

17.

Udd, Bjarne, Vesa Juvonen, Peter M. Andersen, et al.. (2001). Multiple founder effects in spinal and bulbar muscular atrophy (SBMA, Kennedy disease) around the world. European Journal of Human Genetics. 9(6). 431–436. 32 indexed citations

18.

Laing, Nigel G., Francis Mastaglia, Vicki Fabian, et al.. (1998). Genetic studies in a family with autosomal dominant rod and core disease. Journal of Leukocyte Biology. 97(2). 237–45. 1 indexed citations

19.

Bielefeldt‐Ohmann, Helle, David Fitzpatrick, Amanda L. Marzo, et al.. (1994). Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunology Immunotherapy. 39(6). 347–359. 48 indexed citations

20.

Robinson, Bruce, Linda S. Manning, T.I. Christmas, et al.. (1993). The scientific basis for the immunotherapy of human malignant mesothelioma. European Respiratory Review. 3(11). 195–198. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact